Cigna Group is a health company with two main engines. The first is Evernorth Health Services, which manages prescription drug benefits for employers and health plans through its Express Scripts pharmacy benefit business, runs specialty pharmacies that handle complex and expensive medications, and distributes drugs to clinics and hospitals. The second is Cigna Healthcare, which sells medical insurance plans directly to employers and individuals. Most of the money comes in as recurring premiums paid by employers and individuals for coverage, or as fees paid every time a prescription is processed or a service is provided. These two engines feed each other: Cigna Healthcare customers use Evernorth's pharmacy network, and Evernorth sells its services to outside health plans as well. The diagram below traces where the money goes.
How Cigna Group Makes Money
flowchart LR
A["Clients: Employers,
Insurers, TPAs
67,700 colleagues"] --> B["Evernorth:
Pharmacy & Care
216.7B pharmacy rev"]
A --> C["Cigna Healthcare:
Medical Plans
32% ASO, 68% Insured"]
B --> D["Pharmacy Claims
Processing & Rebates
19% from 1 client"]
C --> E["Premium & Fee
Revenue: 251.2B"]
D --> F["Drug Utilization
Data & Formularies"]
E --> G["Net Income &
Cash Flow: 9.6B"]
F --> H["Clinical Insights
& Provider Network
1.7M providers"]
H --> B
H --> C
G --> I["Reinvestment:
Digital, Data,
Technology"]
I --> A
Over the past five years, Cigna's revenue has grown at a remarkable pace, nearly doubling from $131.4 billion in 2021 to $251.2 billion in 2025. Almost all of that growth came from Evernorth, specifically the pharmacy side of the business. As more customers filled more prescriptions, and as expensive specialty drugs became a bigger share of those prescriptions, the dollar volumes flowing through Express Scripts and Accredo Specialty Pharmacy expanded rapidly. But revenue alone does not tell the whole story.
Total Revenue 2021 to 2025 (billions)
Revenue nearly doubled in five years, driven almost entirely by growth in the Evernorth pharmacy services segment.
Gross margin tells a more complicated story. In 2021, Cigna kept about 10.5 cents of gross profit for every dollar of revenue. By 2023 that had risen to about 17.8 cents. But then it fell back: 15.3 cents in 2024 and 14.4 cents in 2025. The pattern makes sense when you understand the pharmacy business. Processing a prescription for a generic drug earns a very thin margin. Processing a prescription for an expensive specialty drug moves a lot of dollars but also costs a lot of dollars. As pharmacy volume surges, revenue grows fast but margin percentage can shrink. The company is getting bigger but not proportionally more profitable on each dollar.
What Is Free Cash Flow?
Free cash flow is the money a company actually has left over after paying its bills and making investments in equipment and technology. It is different from profit on paper. A company can report a profit but still run short of cash. Free cash flow is what management can use to pay down debt, return money to shareholders, or make new investments.
Free cash flow peaked at $11.8 billion in 2023 and has since declined, falling to $9.6 billion in 2025. The company says the drop in 2025 reflects timing of client settlements and the impact of new clients that onboarded in 2024. Net debt has stayed in a relatively stable range, moving from $28.6 billion in 2021 down to $23.1 billion in 2023, then edging back up slightly to $23.8 billion in 2025, partly because of new borrowing to fund an investment in Shields Health Solutions.
$9.6B
Free cash flow in 2025, down from a peak of $11.8B in 2023
2025
milestone
Medicare Businesses Sold to HCSC
In March 2025, Cigna completed the sale of its Medicare Advantage, Medicare drug plans, and related businesses to Health Care Service Corporation for $4.9 billion in cash. This removed a large and shrinking part of the insurance business. It also reduced the number of medical customers by about 1 million. The sale sharpened Cigna's focus on employer health plans and on growing Evernorth's pharmacy services for outside clients.
The Evernorth segment reported adjusted revenues of $234.9 billion in 2025 and pre-tax adjusted income from operations of $7.2 billion, a 3 percent increase over 2024. But its pre-tax margin compressed from 3.5 percent to 3.1 percent, continuing a multi-year slide from 4.2 percent in 2023. The company says this reflects strategic investments and transition costs for a new rebate-free pricing model it is rolling out for pharmacy benefit clients starting in 2027 and 2028. That model is designed to pass drug discounts directly to patients at the pharmacy counter rather than sharing them through rebates later. The transition is expected to cost money in the short term.
What Is a Pharmacy Benefit Manager?
A pharmacy benefit manager, or PBM, sits between drug companies and the people who take medicine. Employers and health plans hire PBMs to negotiate lower drug prices, manage which drugs are covered, and process claims when someone fills a prescription. Express Scripts is one of the largest PBMs in the United States. PBMs make money from fees, from negotiated discounts, and from rebates paid by drug manufacturers.
Evernorth's pharmacy business is heavily concentrated. One single pharmacy benefit client generated approximately 19 percent of Cigna's total external revenue in 2025. The 10 largest pharmacy chains make up 47 percent of stores in its biggest retail network. And Express Scripts renews its largest client contracts roughly every three years. That means the entire revenue base can shift significantly when a major contract is renegotiated or lost. The company says it has renewed or extended contracts with its three largest clients through the end of the decade, which provides some near-term certainty.
19%
Share of total external revenue from a single pharmacy benefit client in 2025
On the insurance side, Cigna Healthcare's medical care ratio rose to 84.4 percent in 2025, up from 81.3 percent in 2023. That ratio measures how much of premium revenue goes to paying medical claims. When it rises, the margin available to cover overhead and generate profit shrinks. The increase was driven mainly by higher costs in the Individual and Family Plans business. Pre-tax adjusted income from operations in Cigna Healthcare fell from $4.5 billion in 2023 to $4.2 billion in 2024 and $4.2 billion again in 2025.
Cigna also faces serious regulatory and legal pressure. The Federal Trade Commission, the Department of Justice, and multiple state attorneys general are investigating practices in pharmacy benefits management and drug pricing. Any of those investigations could result in fines, restrictions on doing business with government programs, or forced changes to how the company operates. Separately, the company has faced public criticism for how it handles claim denials, including a 2023 report describing rejections processed in 1.2 seconds on average without doctor review. Cigna has acknowledged the need to improve and launched a multi-year program it calls Commitments to Better, but reputational and regulatory risk remains elevated.
$749M
Pre-tax cost of the strategic optimization program in 2025, with more charges expected
The company expects its strategic optimization program to generate annualized after-tax savings of at least $500 million, but it also says additional charges beyond the $749 million already recorded in 2025 are anticipated as the program continues.
The Bet
Evernorth can keep growing its pharmacy services revenue fast enough, and profitably enough, to offset margin compression from the rebate-free pricing transition and rising specialty drug costs. The entire financial architecture now depends on this one segment: it generated $234.9 billion of the company's $251.2 billion in 2025 revenue. If the new transparent pricing model attracts large new clients and rebuilds margins after the transition period, the business becomes more durable. If the transition drags profits lower for longer than expected, or if a major client like Centene renegotiates its contract on worse terms, the cash generation that supports debt repayment, dividends, and share repurchases weakens before a replacement growth driver is ready.
Open question
Cigna has made a clear strategic choice: shrink the insurance business, sell Medicare, and double down on pharmacy services through Evernorth. The numbers show revenue surging and debt declining, but free cash flow also declining and margins compressing. A major rebate-free pricing overhaul is underway, regulators are circling, and nearly a fifth of total revenue depends on a single client relationship. Can Evernorth's pharmacy services business sustain and eventually expand its margins through the pricing transition, or will the combination of regulatory pressure, client concentration risk, and rising specialty drug costs erode the profits that the rest of the company depends on?
Compiled · 10-K · FY2025
Medical Cost Estimation
The company must accurately predict how much it will cost to provide health care to customers. If predictions are wrong, even by a small amount, profits can drop significantly. External events like new medical treatments, pandemics, or changes in how people use health care services can make costs unpredictable and hard to control.
Client Contract Risk
The company's largest clients can end contracts or renegotiate prices to be much lower. For example, Express Scripts contracts can be renegotiated every three years based on market conditions. Losing even one major client or getting forced to lower prices could seriously hurt the company's profits.
Pharmacy Network Dependency
The company depends on relationships with 65,000 pharmacies, but the 10 largest chains make up 47 percent of stores in its biggest network. If major pharmacy chains terminate their contracts or demand much better terms, it could reduce customer access to pharmacies and hurt the company's ability to keep clients.
Government Program Changes
The company relies on funding from federal and state government programs, which can be cut or delayed without notice due to budget constraints or political decisions. Sudden funding cuts, payment delays, or retroactive rate reductions could substantially reduce revenue and profitability.
Regulatory and Legal Exposure
The company faces investigations and potential lawsuits from the Federal Trade Commission, Department of Justice, state attorneys general, and other agencies regarding practices in pharmacy benefits management and drug pricing. These investigations can result in fines, sanctions, restrictions on doing business with government programs, or requirements to change business practices.
10-K Item 1A · Risk Factors
